Clinical Study

A Randomized Phase III Trial Of Dabrafenib + Trametinib Followed By Ipilimumab + Nivolumab At Progression Vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression In Patients With Advanced Brafv600 Mutant Melanoma

Posted Date: May 23, 2016

  • Investigator: Nagla Abdel Karim
  • Co-Investigator: Alison Kastl
  • Specialties: Hematology/Oncology, Oncology, Cancer, Skin Cancer
  • Type of Study: Drug

This research study has two treatment regimens, with a potential to crossover from one to the other. Arm A will receive the study drugs ipilimumab and nivolumab first, and at time of disease progression will crossover to Arm C to receive the study drugs dabrafenib and trametinib. Arm B will receive the study drugs dabrafenib and trametinib first, and at time of disease progression will crossover to Arm D to receive the study drugs ipilimumab and nivolumab

Criteria:

To Be Eligible, Patients Must Have Been Diagnosed With Melanoma, A Type Of Skin Cancer, And The Melanoma Has Spread Beyond It's Local Area And Cannot Be Surgically Removed.

Keywords:

Skin Cancer, Melanoma, Cancer, Ea6134, Advanced Brafv600 Mutant

For More Information:

University Of Cincinnati Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.